DR. REDDY'S LABORATORIES, INC.

Dr. Reddy's Laboratories and Alvotech have entered a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar version of Keytruda (pembrolizumab) for global markets.

Eisai and Merck successfully defended a key patent for cancer drug Lenvima against Shilpa Medicare's challenge, with a federal judge ruling the patent describes the invention clearly and in sufficient detail.

The U.S. Food and Drug Administration completed a Good Manufacturing Practice inspection at Dr. Reddy's Middleburgh API facility in New York, resulting in two observations via Form 483.

Esperion Therapeutics has reached a settlement agreement with Micro Labs that prevents the generic manufacturer from marketing a version of NEXLETOL (bempedoic acid) before April 19, 2040.

A federal judge in Illinois ruled that Ingenus Pharmaceuticals can proceed with its patent infringement lawsuit against Nexus Pharmaceuticals regarding cyclophosphamide liquid formulations used in cancer treatment.

Dr. Reddy's Laboratories has secured exclusive rights to promote and distribute Sanofi's novel RSV drug Beyfortus (nirsevimab) in India, expanding their existing vaccine partnership.

The FDA approved 25 first-time generic drugs in the first six months of 2025, including generics for critical medications treating HIV, cancer, and neurological conditions.

A Canadian population-based study found bevacizumab biosimilars Mvasi and Zirabev provided $6,379 CAD in annual cost savings per patient compared to originator Avastin while maintaining equivalent survival outcomes in metastatic colorectal cancer.

Danish pharmaceutical giant Novo Nordisk confirms readiness to launch its blockbuster GLP-1 drug Semaglutide (Ozempic) in India despite patent expiration in January 2026, emphasizing continued market leadership strategy.

Rigel Pharmaceuticals achieved significant revenue growth in 2024, with TAVALISSE sales increasing 12% to $104.8 million and REZLIDHIA sales growing 118% to $23.0 million.